Top Markets
#1 Status Status +19.55%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.58%
#3 GoPlus Security GoPlus Security +17.93%
#4 Wrapped NXM Wrapped NXM +14.89%
#5 Bedrock Bedrock +12.87%
#6 BankrCoin BankrCoin +12.81%
#7 Ontology Gas Ontology Gas +11.52%
#8 Pons Pons +9.76%
#9 DMT-NAT DMT-NAT +8.45%
#10 Janction Janction +7.35%
Coin of the day
Status Status
Settings
Language
ENGLISH
Currency
USD
Theme
Incannex Healthcare Limited Incannex Healthcare Limited

Incannex Healthcare Limited

IHL
Rank in Stocks #33836
Established in Melbourne, Australia, in 2001, Incannex Healthcare Limited,... Established in Melbourne, Australia, in 2001, Incannex Healthcare Limited, which operated as Impression Healthcare Limited until its rebranding in June 2020, is dedicated to the research, development, and commercialization of pharmaceutical products and therapies derived from medicinal cannabinoids and psychedelics. Its offerings include a trio of ultrapure cannabinoid compounds: APIRx-1801 (tetrahydrocannabinol), APIRx-1802 (CBD), and APIRx-1803 (cannabigerol). The company's clinical pipeline features IHL-42X, which has concluded Phase IIa trials for obstructive sleep apnea, and Psi-GAD, currently in Phase IIa development for generalized anxiety disorder. Other compounds having successfully advanced through Phase IIa clinical trials include CanChew Plus for irritable bowel syndrome, APIRx-1601 for vitiligo, APIRx-1602 for psoriasis, and APIRx-1603 for atopic dermatitis. Additionally, MedChew Dronabinol has completed Phase Ia trials for chemotherapy-induced nausea and vomiting. Its pre-clinical portfolio is extensive, including IHL-675A, which has completed studies for inflammatory lung disease, rheumatoid arthritis, and inflammatory bowel disease, alongside IHL-216A for traumatic brain injury/concussion. A broad array of further candidates are actively undergoing pre-clinical investigation, such as MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpetic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for Crohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for cannabis addiction, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, and APIRx-1702 for dry eye syndrome.
Share Price
$0.0270762
Last synced: 2023-11-30
Market Cap
$6.78M
Change (1 day)
-0.66%
Change (1 year)
0.00%
Country
AU
Trade Incannex Healthcare Limited (IHL)

Category

Healthcare
Number of shares outstanding for Incannex Healthcare Limited (IHL)
Number of shares outstanding as of August 2026: 0
According to Incannex Healthcare Limited latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Incannex Healthcare Limited (IHL) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 2.40B -
IN